News

Levée de fonds de 100 millions USD pour notre client Oculis !
Patents

100 million USD fundraising for our client Oculis!

Founded in December 2017, Oculis is an international biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases purposefully driven to save sight and improve eye care. 
 
This latest round of funding strengthens Oculis' position and enables it to continue its growth and support the development of its innovative product candidates for ophthalmic diseases.
 
In 2023, Oculis announced its listing on Nasdaq U.S. followed in 2024 by its listing on Nasdaq Iceland main market. 

Our expert Denis Bourgarel, Partner, French and European Patent Attorney, assists Oculis with IP strategy and operations.
 
Congratulations to this innovative company with strong track record of milestones delivery since inception! 
 
For further information: https://oculis.com/

Share on: